AIP
MRNA icon

Arrowpoint Investment Partners’s Moderna MRNA Stock Holding History

Arrowpoint Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,400
Closed -$225K – 1121
2024
Q4 		$225K Buy
+5,400
New +$258K 0.05% 358

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowpoint Investment Partners's MRNA Position: Q1 2026 in Review

Arrowpoint Investment Partners opened a new position in Moderna (MRNA) in Q1 2026: 17,097 shares worth $869K. The stake represents 0.77% of the portfolio and ranks #26 among its holdings.

723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Arrowpoint Investment Partners held 17,097 shares of Moderna worth $869K as of Q1 2026.
  • Moderna was a new Arrowpoint Investment Partners position in Q1 2026.
  • Moderna made up 0.77% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #26 holding.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.